Real-world use of once-weekly semaglutide in Thai patients with type 2 diabetes mellitus in a private hospital setting
doi.org/10.15605/jafes.038.01.11
- Author:
Yotsapon Thewjitcharoen
1
;
Nalin Yenseung
1
;
Siriwan Butadej
1
;
Soontaree Nakasatien
1
;
Phawinpon Chotwanvirat
1
;
Waralee Chatchomchuan
1
;
Ekgaluck Wanothayaroj
1
;
Sirinate Krittiyawong
1
;
Thep Himathongkam
1
Author Information
1. Theptarin Hospital, Bangkok, Thailand
- Publication Type:Journal Article
- Keywords:
semaglutide;
once-weekly
- MeSH:
real-world;
Thai
- From:
Journal of the ASEAN Federation of Endocrine Societies
2023;38(1):21-28
- CountryPhilippines
- Language:English
-
Abstract:
Objective:To evaluate the real-world use of once-weekly semaglutide among Thai patients with type 2 diabetes (T2DM) in a private hospital setting.
Methodology:A retrospective review of Thai patients with T2DM who have initiated semaglutide for at least 1 month between June 2020 and March 2022 at Theptarin Hospital, Bangkok, Thailand.
Results:A total of 58 patients (50% female, mean age 55.6 ± 15.9 years, with duration of diabetes 12.6 ± 10.3 years, BMI 31.5 ± 4.4 kg/m2, baseline HbA1c 7.9 ± 1.9%, with prior GLP-1 RA use 24.1%, and concomitant SGLT2i intake (41.4%) were included. During a median follow-up of 6 months, the mean serum HbA1c level reduction was 1.3 ± 1.7% with weight loss of 4.7 ± 4.1 kg. The proportion of patients who achieved optimal and sustainable glycemic control (HbA1c <7.0%) increased from 43.1% to 55.8% at the last follow-up. The proportion of patients reaching both HbA1c targets of <7.0% and 5% weight loss was 27.8%. No cases of pancreatitis, cancer, or progressive retinopathy were observed.
Conclusion:In this single center undertaking, it was shown that in among persons with T2DM and obesity in Thailand, semaglutide was associated with short-term glycemic control and weight loss comparable with what has been observed in randomized clinical trials and other RWE.
- Full text:2493-Article Text-23111-1-10-20230516.pdf
